Monthly dosage specifications of Everolimus/Afinitor

Everolimus (Everolimus) is an oral immunosuppressant that mainly exerts its anti-tumor and anti-immune functions by inhibiting the mTOR (mammalian target of rapamycin) signaling pathway. It is widely used in the treatment of many types of cancer and certain genetic diseases, such as breast cancer, neuroendocrine tumors, renal cell carcinoma, tuberous sclerosis, etc. The monthly dose of everolimus is usually adjusted according to different diseases and patient conditions to ensure maximum therapeutic effect and minimize side effects.

For patients with breast cancer, neuroendocrine tumors, renal cell carcinoma, and renal angiomyolipoma associated with tuberous sclerosis complex (TSC), the standard recommended dose is 10 mg once daily. This is a general treatment plan and suitable for most patients. In practice, dosage adjustments depend on patient tolerance and clinical response. If a patient experiences serious side effects, the doctor may lower the dose or temporarily stop the medication to control the side effects. .

For patients with tuberous sclerosis-related subependymal giant cell astrocytoma (SEGA), the recommended starting dose is 4.5 mg/m² once daily. Such patients usually need to calculate the dose based on body surface area, rather than relying solely on weight or age. The purpose is to accurately adjust the drug dose to ensure that the concentration of the drug in the blood is maintained between 5-15ng/mL, so that the drug can exert its effect within the optimal range and reduce the occurrence of side effects. For such patients, blood drug concentration monitoring is particularly necessary to avoid drug concentrations that are too high or too low.

For patients with partial-onset epilepsy associated with tuberous sclerosis, the recommended starting dose is5 mg/m² taken orally once daily. Similar to patients with SEGA, the dose in patients with epilepsy needs to be adjusted based on body surface area. During the treatment process, the patient's blood concentration needs to be maintained between 5-15 ng/mL, which usually requires finer adjustments. Regularly check the drug concentration and side effects to ensure the patient's therapeutic effect and safety.

Reference materials:https://www.drugs.com/everolimus.html